openPR Logo
Press release

Fibromyalgia Therapeutics - Pipeline Analysis 2018

02-12-2018 11:45 AM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Fibromyalgia therapeutic pipeline is expected to experience a positive trend in the coming years. Prevalence of fibromyalgia is increasing due to very large number of patients suffering from lifestyle disease, psychological stress, trauma, tension, headaches, anxiety and depression. Some of the significant factors driving the pipeline for fibromyalgia include rising prevalence of fibromyalgia and the increasing health awareness among the population, globally. According to the National Fibromyalgia and Chronic Pain Association, around 10 million Americans are suffering from fibromyalgia in the U.S. Also, nearly 2% to 4% of world’s population was affected with fibromyalgia in 2015. It is more prevalent in women than in men. The risk factors of developing fibromyalgia include family history and other disorders such as osteoarthritis, rheumatoid arthritis or lupus.

Explore Report Sample at:

Fibromyalgia is a disease that affects muscles and soft tissues in the body. It is believed that fibromyalgia amplifies painful sensations by affecting the way brain processes signals. Symptoms of fibromyalgia include fatigue, excessive pain and cognitive difficulties. Fibromyalgia is usually associated with other diseases including irritable bowel syndrome, migraine, interstitial cystitis, temporomandibular joint disorders, anxiety and depression. The causes of fibromyalgia can be physical or emotional trauma, genetic factors and infections. The complications that occur due to having fibromyalgia include pain and lack of sleep that can interfere with the ability to function at home or at work. Fibromyalgia can be easily diagnosed by blood tests that include complete blood count, erythrocyte sedimentation rate, cyclic citrullinated peptide test, rheumatoid factor and thyroid function tests. The treatment of fibromyalgia include self-care and medications. Medications for relieving the symptoms of fibromyalgia include pain relievers such as acetaminophen, ibuprofen or naproxen sodium, antidepressants namely; duloxetine and milnacipran and anti-seizure drugs namely; gabapentin and pregabalin. The therapies which can improve fibromyalgia condition include physical therapy, occupational therapy and counselling. Physical therapy helps in improving strength, flexibility and stamina while occupational therapy helps to make adjustments in work area. There are other alternative treatments that are also present for treating fibromyalgia, such as, acupuncture, massage therapy and yoga.

Explore Report at:

Some of the companies having a pipeline of fibromyalgia therapeutics include Intellipharmaceutics International, Inc., Daiichi Sankyo Company Ltd., KPI Therapeutics, Inc., Merck & Co. Inc., Theravance Biopharma Inc., Pfizer Inc., Astellas Pharma, Inc., Immune Therapeutics, Inc., Zynerba Pharmaceuticals, Inc., Vitality Biopharma, Inc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fibromyalgia Therapeutics - Pipeline Analysis 2018 here

News-ID: 939876 • Views: 379

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ As per the findings of research, it

All 5 Releases

More Releases for Fibromyalgia

Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues. Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD. Fibromyalgia can be diagnosed if the patient had widespread pain
Fibromyalgia Treatment Ingredient Market | 2021 Trends, Size, Share
The global fibromyalgia treatment market size is expected to reach USD 1,414.4 million by 2027, exhibiting a CAGR of 9.2% during the forecast period. Fibromyalgia Treatment Ingredient Industry is segmentedBy Product Type (Single Energy Mode, Dual Energy Mode), By Vehicle Type (Passenger Cars, Commercial Vehicles) and regional forecast 2021-2027 Request a Sample Copy of the Research Report: Strong Pipeline Products to Augment Growth The prominent companies are focused on introducing innovative therapies
Fibromyalgia Treatment Market Global Industry Insights 2018-2026
Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue and localized tenderness affecting individuals mentally, physically and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration and depression. Fibromyalgia symptoms
Anticonvulsant Market for Fibromyalgia Optimistic Opportunities 2025
Anticonvulsant Market for Fibromyalgia: Snapshot Anticonvulsants are pharmacological agents from a diverse group that are used for the treatment of epileptic seizures. Anticonvulsants are increasingly in demand on account of their use for the treatment of bipolar disorders. They are also used for the treatment of borderline personality disorder. Anticonvulsants act as stabilizers of mood and helps in the treatment of neuropathic pain. They suppress the rapid, excessive firing of neurons
Chinese Fibromyalgia Market Research Report- Forecast to 2022
Market Scenario: Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart